Clinical Trial Update: A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 trial to evaluate the mechanism of action of CP-690,550 (tofacitinib) in rheumatoid arthritis and posted the results in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2013-01-09